This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G60.0 | Special Copayment Reduction: V169 | 5 years |
| B. Synonyms | Charcot-Marie-Tooth disease, hereditary motor and sensory neuropathy types I–IV, Dejerine-Sottas disease, Roussy-Lévy syndrome, hypertrophic neuropathy of infancy, peroneal muscular atrophy (axonal type, hypertrophic type), hereditary motor and sensory neuropathy (general) |
| C. Adult onset | Likelihood of first onset in adulthood: low to moderate — CMT1A usually begins in the teens to 20s, CMT2 later, and Dejerine-Sottas in infancy |
| 1. History | Simultaneous independent descriptions by Charcot, Marie, and Tooth in 1886; HMSN classification by Dyck and Lambert in 1968; discovery of the PMP22 duplication in 1991 |
| 2. Causes | PMP22 duplication (70–80% of CMT1A), MPZ, GJB1, MFN2, and more than 80 other genes; demyelinating, axonal, and intermediate types |
| 3. Genetics | Autosomal dominant (CMT1A, CMT1B, CMT2A), X-linked (CMTX1/GJB1), autosomal recessive (CMT4/Dejerine-Sottas) |
| 4. General epidemiology | Prevalence 1/2,500–1/1,214; the most common hereditary neuromuscular disease, estimated at several thousand or more patients in Korea; CMT1A accounts for about 50% of all cases |
| 5. Pathophysiology | PMP22 overexpression causes Schwann cell dysfunction → demyelination and axonal degeneration → distal muscle atrophy and sensory loss |
| 6. Symptoms | Distal weakness and atrophy (lower limbs first), foot deformities (pes cavus, clubfoot), distal sensory abnormalities, absent deep tendon reflexes |
| 7. Signs | Inverted champagne bottle legs, pes cavus, hammer toes, absent knee reflex, nerve hypertrophy (hypertrophic type), scoliosis |
| 8. Screening | Confirmation of family history, nerve conduction study (NCS), clinical phenotype assessment (CMT neuropathy score, CMTES) |
| 9. Diagnosis | NGS gene panel (including PMP22 MLPA), nerve ultrasound, nerve biopsy (if needed), electrophysiological classification |
| 10. Treatment | Currently symptomatic treatment (rehabilitation, orthoses, orthopedic surgery); clinical trials of govorestat (SORD-deficiency CMT), ASO, and gene therapy underway |
| 11. Prognosis | CMT1A slowly progressive, most maintain ambulation; Dejerine-Sottas and CMT4 severe from early on; life expectancy near normal |
| 12. Prevention | PGT-M and prenatal diagnosis; avoid neurotoxic drugs; prevent falls and trauma; rehabilitation to maintain muscle strength |
| 13. References | Rossor AM et al. Lancet Neurol 2013 and 9 other papers |
The origin of Charcot-Marie-Tooth disease (CMT) goes back to 1886. French neurologist Jean-Martin Charcot and his student Pierre Marie in Paris, and British physician Howard Henry Tooth in Cambridge, independently and almost simultaneously described a hereditary neuropathy characterized by distal muscle atrophy. Charcot and Marie named it "peroneal nerve neuropathy with progressive muscular atrophy," and Tooth, in his doctoral thesis, named it the "peroneal type of progressive muscular atrophy."
In the first half of the 20th century, clinically diverse forms of hereditary neuropathy were described. In 1893, the French physicians Joseph Jules Dejerine and Jules Sottas reported a hypertrophic neuropathy beginning in infancy and progressing severely (Dejerine-Sottas disease), and in 1926 Roussy and Lévy described a relatively mild form of hereditary neuropathy (Roussy-Lévy syndrome). All of these were later shown to belong to the CMT spectrum.
The basis of the classification system was laid in 1968 when Dyck and Lambert applied electrophysiological criteria to distinguish a hypertrophic form with markedly reduced nerve conduction velocity (NCV) (HMSN type I) from an axonal form with near-normal NCV (HMSN type II). This demyelinating/axonal classification became the prototype of the current CMT1/CMT2 classification.
The molecular genetic revolution began in 1991 with the discovery that a 1.5 Mb duplication at band 11.2 of the short arm of chromosome 17 (17p11.2) causes CMT1A. In 1993 it was then confirmed that the PMP22 gene lies within the duplication. Over the following 30 years, more than 80 CMT causative genes were identified, and the introduction of next-generation sequencing (NGS) greatly improved the genetic diagnostic rate. Preclinical studies of ASO gene therapy for CMT1A and clinical trials of targeted therapies for various genotypes are currently active.
CMT is a group of hereditary peripheral neuropathies caused by pathogenic variants in various genes responsible for the function and structure of peripheral nerves. More than 80 causative genes have been identified to date, and the disease is subdivided by causative gene and neuropathological type. Clinically and electrophysiologically, it is broadly divided into demyelinating (CMT1), axonal (CMT2), and intermediate (intermediate CMT) types.
The most common cause is CMT1A, in which a 1.5 Mb tandem duplication at 17p11.2-p12 on the short arm of chromosome 17 results in 3 or more copies of the PMP22 (peripheral myelin protein 22) gene. It accounts for about 50% of all CMT and about 70–80% of CMT1, and is the most common single genotype. PMP22 deletion causes hereditary neuropathy with liability to pressure palsies (HNPP).
The second most common demyelinating cause is CMT1B, due to variants of the MPZ (myelin protein zero, 1q22) gene. CMT1B is highly clinically heterogeneous, ranging from severe infantile onset (Dejerine-Sottas-like) to mild adult onset. Variants of the GJB1 (connexin 32, Xq13.1) gene cause X-linked CMT (CMTX1), which is more severe in males. Variants of the mitochondrial fusion protein MFN2 (1p36.2) cause CMT2A, the most common axonal type. Many other genes are also involved, including NEFL, GDAP1, LITAF, EGR2, SIMPLE, PRPS1, AIFM1, and SH3TC2.
Dejerine-Sottas disease (DSS) is a severe demyelinating neuropathy caused mainly by severe variants of the MPZ, PMP22, and EGR2 genes or by autosomal recessive genes (PRX, NDRG1, SH3TC2, etc.). Autosomal recessive CMT (CMT2Q) due to biallelic loss-of-function variants of the SORD (sorbitol dehydrogenase) gene is a recently discovered, relatively common form; adult onset is frequent, and a phase 3 trial of a targeted small-molecule drug (govorestat) is underway.
CMT is not a single disease but a group of neuropathies with extremely high genetic heterogeneity, and modes of inheritance are also diverse, including autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, and rarely mitochondrial inheritance. The most common mode of inheritance is autosomal dominant.
CMT1A (PMP22 duplication): autosomal dominant, complete penetrance. A substantial proportion of sporadic cases arise from de novo duplications due to non-allelic homologous recombination (NAHR) at 17p11.2 during sperm or egg formation. CMT1A is therefore diagnosed even without a family history. CMT1B (MPZ variants): autosomal dominant; expressivity and penetrance vary by variant. CMTX1 (GJB1 variants): X-linked; female heterozygotes are typically mild and male hemizygotes severe, but clinically significant neuropathy can also occur in females. CMT2A (MFN2 variants): autosomal dominant; some recessive variants also reported. CMT4 (Dejerine-Sottas, autosomal recessive demyelinating type): many genes including SH3TC2, GDAP1, NDRG1, PRX, MTMR2; complete penetrance, severe.
For genetic diagnosis of CMT, NGS-based gene panel testing is recommended as the first-line test. Because PMP22 duplication/deletion is difficult to detect with standard NGS, MLPA (multiplex ligation-dependent probe amplification) or array CGH must be performed in parallel. The diagnostic rate is over 90% in typical CMT1 but only 30–50% in the axonal type (CMT2). When interpreting genetic variants, distinguishing pathogenic variants, variants of uncertain significance (VUS), and benign variants is important for clinical management.
In genetic counseling, the risk of an affected child for a parent with CMT1A (PMP22 duplication) is 50%. Preimplantation genetic testing (PGT-M) and prenatal diagnosis are available. Because variable expressivity is large, genetic counseling should include that symptom severity can differ greatly even within the same family. In CMT4 (autosomal recessive), when both parents are carriers, the risk of an affected child is 25%.
CMT is the most common hereditary neuromuscular disease. The worldwide prevalence is reported as about 1/2,500–1/1,214, including the whole group of hereditary neuropathies. The number of patients in the United States is estimated at about 130,000–150,000. In Korea, there are estimated to be several thousand or more patients, managed under rare disease Special Copayment Reduction code V169.
CMT1A (PMP22 duplication) accounts for about 50% of all CMT and is the most common single genotype. CMT2A (MFN2 variants) is the most common form of CMT2, and CMTX1 (GJB1 variants) accounts for about 10–15% of the total. Genotype distribution differs by ethnicity and region, so genotype frequencies in Asian populations, including Korea, may differ somewhat from those in Western populations. Founder mutations are common in certain regions and ethnic groups.
Age of onset differs greatly by genotype. CMT1A usually begins in the teens to 20s, and in some cases after the 30s. CMT2A and CMT2 tend to have a later age of onset than CMT1, and some forms begin after the 40s–50s. Dejerine-Sottas (CMT4, DSS) and hypertrophic neuropathy of infancy (CCFDN) begin in infancy or early childhood and follow a severe course. Roussy-Lévy syndrome may remain mild and unrecognized until adulthood.
The male-to-female prevalence ratio is equal in most genotypes, but males are more severely affected in CMTX1. Diagnostic delay is common; even with a family history, many patients go undiagnosed for years or are recognized only as having "strange feet." Since the introduction of CMT patient registries and the spread of NGS, the diagnostic rate and the accuracy of genotype classification have improved.
The core pathophysiology of CMT1A is overexpression of PMP22 protein due to the presence of 3 copies of the PMP22 gene. PMP22 is a component of the compact myelin of Schwann cells (about 2–5% of the total) and is involved in myelin formation and maintenance and in regulating Schwann cell proliferation and differentiation. Overexpressed PMP22 accumulates in the endoplasmic reticulum (ER), causing ER stress and interfering with normal myelination, resulting in defective myelin sheath formation (dysmyelination).
The neuropathology of CMT1A is characterized by "onion bulb" formation. As Schwann cells go through repeated demyelination and attempts at remyelination, concentric layers of Schwann cell processes build up around the nerve, forming onion bulb structures that appear as nerve hypertrophy. Nerve conduction velocity (MCV) is generally severely reduced, to about 15–35 m/s. Over the long term, the axons are also damaged (secondary axonal degeneration) due to loss of myelin support, and this axonal degeneration is most closely associated with clinical disability (weakness, functional impairment).
In the axonal type (CMT2), dysfunction of the axon itself, rather than of the Schwann cells, is the primary cause. MFN2 variants (CMT2A) impair mitochondrial fusion, disturbing mitochondrial distribution and energy supply, so axonal degeneration progresses in the distal portions of long axons. NEFL variants (CMT2E) cause impaired axonal transport through abnormal neurofilament assembly. In CMT2, nerve conduction velocity is normal or mildly reduced (MCV >38 m/s), but reduced compound muscle action potential (CMAP) amplitude is prominent.
In SORD-deficiency CMT (CMT2Q), loss of SORD enzyme function blocks sorbitol metabolism, causing excessive intracellular accumulation of sorbitol. Excess sorbitol causes osmotic stress, oxidative stress, and abnormal energy metabolism, damaging peripheral nerve axons. This mechanism is the rationale for targeted therapy with govorestat (an aldose reductase inhibitor) blocking the sorbitol precursor (fructose).
The core clinical symptoms of CMT are distal-predominant progressive weakness and muscle atrophy, distal sensory abnormalities, absent or reduced deep tendon reflexes, and foot deformities. Symptoms begin in the distal lower limbs and gradually progress to the distal and then proximal upper limbs in a length-dependent pattern. In CMT1A, symptoms usually appear in the teens to 20s, but individual variation is large.
Early symptoms include abnormal gait, difficulty running, recurrent ankle sprains, difficulty wearing shoes (foot deformities), and weakness of toe lifting. "Foot drop" due to weak dorsiflexion of the ankle and foot, and the compensatory "steppage gait," are typical. The most common foot deformities are pes cavus, equinovarus, and hammer toe. Pes cavus develops from atrophy of the intrinsic foot muscles and is more severe in patients with earlier onset.
Weakness of the distal upper limbs (intrinsic hand muscles, forearm) appears several to more than ten years after lower limb symptoms, presenting as impaired fine hand movements such as writing, buttoning, and opening bottle caps. Sensory abnormalities are marked by reduced vibration and position sense distally (feet, ankles, distal lower legs), and loss of pain and temperature sensation may also be present. Some patients complain of neuropathic pain (burning, tingling). Upper limb tremor is particularly prominent in Roussy-Lévy syndrome.
In severe forms (Dejerine-Sottas, CMT4), hypotonia, delayed motor development, and inability or delay in independent walking appear from infancy, and scoliosis, respiratory muscle weakness, and dysphagia may be present. The severe form of CMT2A (MFN2 variants) is accompanied by visual abnormalities (optic atrophy) and hearing abnormalities. Autonomic dysfunction is relatively mild in CMT, but abnormal sweating and orthostatic hypotension occur in some patients.
On physical examination, the characteristic sign of CMT is the "inverted champagne bottle" or "stork leg" appearance of the lower limbs due to distal muscle atrophy. The distal third of the lower leg and below is severely atrophied while the proximal part (thigh) is relatively preserved, creating a dramatic contrast. This finding is especially marked in CMT1A and becomes more prominent as the disease progresses.
On examination of foot deformities, pes cavus is the most common CMT-related sign, with an excessively high plantar arch. Hammer toes and claw toes are present. When combined with varus deformity of the foot, a cavovarus foot deformity forms. Calluses and pressure ulcers repeatedly develop on the heel and lateral side of the foot.
On neurological examination, loss of the ankle deep tendon reflex (Achilles reflex) is the earliest and most consistent finding. The knee reflex is also reduced or absent, and upper limb tendon reflexes are lost as the disease progresses. Pyramidal signs (Babinski response) do not typically appear in CMT; if present, a coexisting central nervous system lesion should be suspected. In the hypertrophic type (CMT1), enlargement of superficial nerves such as the sural and radial nerves is palpable.
Scoliosis occurs in about 20–37% of CMT patients and is more common in the hypertrophic type. Severe scoliosis can lead to reduced respiratory function, so regular pulmonary function testing is needed. The CMT Neuropathy Score (CMTNS, or its revised version CMTES) is a standard clinical assessment tool that integrates muscle strength, pinprick sensation, vibration sense, and nerve conduction measures to quantify severity on a 0–36 scale (CMTNS).
The key to CMT screening is confirming family history and a nerve conduction study (NCS). In patients with distal weakness, foot deformities, gait abnormalities, recurrent ankle sprains, and absent tendon reflexes, especially those with a family history, CMT should be considered first in the differential. For screening purposes, when there is a confirmed patient in the family, clinical examination and nerve conduction studies are performed in the other family members.
Nerve conduction studies are the key tool for CMT screening and type classification. Based on median nerve motor conduction velocity (MCV), < 38 m/s is classified as demyelinating (CMT1), ≥ 38 m/s as axonal (CMT2), and 25–45 m/s as intermediate. In CMT1A, MCV is usually in the 20–30 m/s range. Median nerve conduction velocity is reduced uniformly and relatively independently of clinical expression, making it stable for diagnostic screening.
Quantification of clinical severity with the CMT Neuropathy Score (CMTNS/CMTES) is used for screening and follow-up. Scores are classified as 0–10 (mild), 11–20 (moderate), and 21 or more (severe). Nerve ultrasound noninvasively determines whether the nerve cross-sectional area (CSA) is enlarged, helping distinguish the hypertrophic type from the axonal type. On sural nerve ultrasound, CSA ≥9 mm² has been proposed as an ancillary criterion for the diagnosis of CMT1.
As a screening genetic test, MLPA to detect PMP22 duplication is performed first. This rapidly and cost-effectively screens for CMT1A, which accounts for 50% of all CMT. If PMP22 is negative, testing proceeds stepwise according to clinical phenotype and nerve conduction pattern in the order GJB1 (male CMT1, suspected X-linked), MPZ (CMT1B), MFN2 (suspected CMT2A), or switches to an NGS panel.
Confirmation of CMT is made by integrating the clinical phenotype, nerve conduction studies, and genetic testing. The standard diagnostic algorithm uses PMP22 MLPA as step 1 and, if negative, a broad CMT NGS gene panel (including more than 80 genes) as step 2. The NGS panel can be extended to whole-exome sequencing (WES) or whole-genome sequencing (WGS), which increases the diagnostic rate especially for rare recessive genotypes.
Nerve conduction studies are essential for genotype classification (demyelinating/axonal/intermediate) and for determining the extent of involvement (length-dependent vs. non-uniform conduction block). Uniform slowing of conduction velocity is characteristic of CMT1, whereas non-uniform conduction block suggests polyneuritis (CIDP) and requires differentiation. Electromyography (EMG) evaluates denervation and reinnervation findings to quantify disease activity and the degree of axonal damage.
Nerve biopsy is currently not performed routinely and is considered selectively when diagnosis is not possible by genetic testing or to exclude non-genetic causes (acquired neuropathy). CMT1 biopsies show onion bulb formation, demyelination and remyelination, and enlarged Schwann cell nuclei. CMT2 shows prominent axonal loss and superficial fibrosis with few onion bulbs.
Important differential diagnoses are chronic inflammatory demyelinating polyneuropathy (CIDP), hematologic neuropathies, toxic and metabolic neuropathies, and other hereditary neuropathies (Friedreich ataxia, giant axonal neuropathy, vitamin E deficiency). Distinction from CIDP is clinically important because CIDP responds to immunosuppressive treatment; it is differentiated by elevated CSF protein, non-uniform conduction block, and response to immunotherapy. Genetic testing is essential in CMT1 patients without a family history (de novo variants) to avoid overdiagnosis of CIDP.
Disease-modifying therapy for CMT has not yet reached standard clinical use, but clinical trials are underway for some genotypes. The mainstays of treatment are rehabilitation, prescription of assistive devices, pain management, and management of complications (foot deformities, scoliosis, respiratory impairment).
Rehabilitation is central to CMT management. Strengthening exercises (especially low-intensity resistance exercise of distal muscles), aerobic exercise, balance training, and stretching help maintain function. There is evidence that excessive high-intensity eccentric exercise may actually harm denervated muscle, so continued exercise at moderate or lower intensity is recommended. Physical and occupational therapy teach compensatory strategies for activities of daily living.
Among assistive devices, the ankle-foot orthosis (AFO) is most useful for improving foot drop and gait abnormalities. Carbon fiber AFOs are lightweight with excellent support. Custom shoes, shock-absorbing insoles, and canes or walkers are also prescribed as needed. Orthopedic surgery considered includes pes cavus correction (fascia release, tendon transfer, metatarsal osteotomy), ankle stabilization, hammer toe correction, and spinal fusion for severe scoliosis.
For neuropathic pain, neuropathic pain medications such as gabapentin, pregabalin, duloxetine, and amitriptyline are used. Note that in CMT patients certain drugs can cause neurotoxicity and worsen symptoms, so neurotoxic drugs such as vincristine, paclitaxel, thalidomide, amiodarone, and lidocaine must be avoided. In SORD-deficiency CMT (CMT2Q), a phase 3 trial of the aldose reductase inhibitor govorestat (AT-007) is underway. For CMT1A, PMP22 mRNA-silencing ASOs (antisense oligonucleotides), AAV-based gene therapy, and small-molecule modulators of PMP22 expression are in preclinical and early clinical stages.
The prognosis of CMT differs greatly by genotype. The most common form, CMT1A, progresses slowly, and most patients maintain independent ambulation in adulthood. Studies show that about 75–80% of CMT1A patients maintain the ability to walk into their 60s, and only 5–10% need a wheelchair. However, occupational limitations and reduced quality of life due to foot deformities, pain, fatigue, and reduced hand function are considerable.
Dejerine-Sottas disease (severe demyelinating type, CMT4) and the severe infantile-onset form of CMT2 show marked functional impairment from infancy, and patients often fail to achieve independent walking or lose it early. The severe form of CMT2A (MFN2) adds visual loss due to optic atrophy. In CMT3 (also used as a synonym for Dejerine-Sottas), restrictive lung disease due to respiratory muscle weakness and scoliosis can be life-threatening.
The clinical progression of CMT1A is slow and nonlinear. In long-term follow-up studies of adult CMT1A patients, the annual change in CMTNS is about 0.3–0.7 points, showing very slow progression. CMT1A is known to have almost no effect on life expectancy itself, but it can affect lifespan when serious complications (respiratory failure, aspiration pneumonia, fall-related trauma) occur. Psychological effects (depression, anxiety, socioeconomic burden from job loss) are also important considerations in the long-term prognosis.
At regular follow-up (every 6–12 months), the rate of progression and complications are monitored with nerve conduction studies, CMTNS/CMTES, pulmonary function (FVC), and spinal X-rays. Receiving up-to-date clinical trial information through the CMT association (CMTA) and international CMT registries, and considering participation in suitable clinical trials, is currently the best management.
Primary prevention of CMT (preventing the disease itself) is possible through genetic counseling and genetic diagnosis at the family planning stage. For patients with a confirmed pathogenic variant or carrier couples, preimplantation genetic testing (PGT-M) allows selective transfer of only embryos without the pathogenic gene. Prenatal diagnosis (chorionic villus sampling or amniocentesis) is also possible. Because most CMT1A is autosomal dominant, when one parent is affected, 50% of the children inherit the gene. For carrier couples of CMT4 (recessive), the risk is 25%.
An important secondary prevention rule is avoidance of neurotoxic drugs. In CMT patients, cases have been reported of certain chemotherapeutic agents (vincristine, cisplatin, paclitaxel, etoposide, Taxol), antiarrhythmics (amiodarone), anti-leprosy drugs (thalidomide), antibiotics (nitrofurantoin, chloramphenicol), and neurotoxic anesthetics rapidly worsening CMT symptoms. When CMT patients are prescribed drugs by other departments, they must disclose their CMT diagnosis, and the CMT network's latest drug caution list (CMTA "Drug Checker") should be checked before prescribing.
Fall prevention is central to safety management in CMT patients. Because of foot drop, sensory abnormalities, and balance impairment, the risk of falls and fractures is higher than in the general population. Environmental improvements are needed, such as wearing appropriate AFOs, non-slip flooring, installing bathroom grab bars, ensuring night lighting, and adjusting exercise with fall risk. Regular strengthening exercise and balance training also help prevent falls. In the children of parents with CMT, early diagnosis through early nerve conduction studies and clinical evaluation, followed by proactive introduction of rehabilitation and assistive devices, helps prevent complications.